Alkermes和Eisai在2025年世界睡眠会议上展示了令人充满希望的精神病药物试验结果。 Alkermes and Eisai present promising narcolepsy drug trial results at World Sleep 2025 conference.

Alkermes在2025年世界睡眠大会上介绍了积极的阶段2试验结果。 Alixorexton是治疗1型精神病的药物。 Alkermes presented positive Phase 2 trial results at the World Sleep 2025 conference for Alixorexton, a drug treating narcolepsy type 1. 研究表明,病人的觉醒、认知功能和疲劳症都有显著改善。 The study showed significant improvements in wakefulness, cognitive function, and reduced fatigue for patients. Eisai还分享了具有希望的E2086年第一阶段b试验数据,指出与目前的治疗相比,日间戒备状态有所改善。 Eisai also shared promising Phase Ib trial data for E2086, noting improvements in daytime alertness compared to current treatments. 这两种药物仍在开发之中,尚未得到批准。 Both drugs are still in development and not yet approved.